免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Thin Nevus-Associated Melanoma: Beyond MIA Score Risk Stratification.
Thin Nevus-Associated Melanoma: Beyond MIA Score Risk Stratification.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
痣相关黑色素瘤(NAM)常在早期被诊断,但薄肿瘤内的风险异质性仍鲜有表征。经典组织病理学特征能否细化该亚组的风险分层尚不清楚。
评估组织病理学特征,特别是核分裂活性和TIL(肿瘤浸润淋巴细胞)(TILs),在薄痣相关黑色素瘤(pTis-pT1a)(<0.8 mm)中的预后意义。
对在一家三级皮肤肿瘤中心连续诊断的138例经组织学确诊的NAM患者进行回顾性队列研究(2006年10月至2023年12月)。按照AJCC第8版重新评估分期。对100例薄NAM(pTis-pT1a)患者进行预设亚组分析,评估10年内的不良结局(远处转移或死亡)。采用χ 2检验和logistic回归评估相关性。
中位年龄为53.5岁(IQR 44.0-63.8);60.9%为男性。中位Breslow厚度为0.57 mm(IQR 0.4-0.8)。5年总生存率为90.9%,10年总生存率为86.0%。在薄NAM中,8例患者(8%)出现不良结局。核分裂活性≥ 1/mm 2与更高的不良事件发生率相关(10.9% vs. 2.8%;OR,4.30;95% CI,0.51-36.43;p = 0.18)。在TIL类别中观察到梯度:无TILs者不良事件发生率为13.8%,非活跃性TILs者为7.3%,活跃性TILs者为0%(p = 0.24)。探索性多变量分析显示效应方向一致,但未达到统计学显著性。
薄痣相关黑色素瘤并非均属低风险。核分裂活性和TILs缺失与更高的不良事件发生率相关,提示经典组织病理学特征可能细化早期NAM的风险分层。
Background : Nevus-associated melanomas (NAM) are frequently diagnosed at an early stage, yet risk heterogeneity within thin tumors remains poorly characterized. Whether classical histopathologic features can refine risk stratification in this subgroup is unclear. Objective : To evaluate the prognostic significance of histopathologic features, particularly mitotic activity and tumor-infiltrating lymphocytes (TILs), in thin nevus-associated melanoma (pTis-pT1a) (<0. 8 mm).
Methods : Retrospective cohort study of 138 consecutive patients with histologically confirmed NAM diagnosed at a tertiary dermatologic oncology center (October 2006-December 2023). Staging was reassessed as per AJCC 8th edition.
A predefined subgroup analysis of 100 patients with thin NAM (pTis-pT1a) evaluated adverse outcomes (distant metastasis or death) within 10 years. Associations were assessed using χ 2 tests and logistic regression. Results : Median age was 53. 5 years (IQR 44. 0-63. 8); 60. 9% were male. Median Breslow thickness was 0. 57 mm (IQR 0. 4-0. 8).
Overall survival was 90. 9% at 5 years and 86. 0% at 10 years. Among thin NAM, eight patients (8%) experienced adverse outcomes. Mitotic activity ≥ 1/mm 2 was associated with higher adverse event rates (10. 9% vs. 2. 8%; OR, 4. 30; 95% CI, 0. 51-36. 43; p = 0. 18). A gradient was observed across TIL categories: adverse events occurred in 13. 8% with absent TILs, 7. 3% with non-brisk, and 0% with brisk TILs ( p = 0.
24). Exploratory multivariable analysis showed consistent effect directions without reaching statistical significance. Conclusions : Thin nevus-associated melanomas are not uniformly low risk. Mitotic activity and absent TILs were associated with higher adverse event rates, suggesting that classical histopathologic features may refine risk stratification in early-stage NAM.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。